Biosimilar Drugs for Multiple Sclerosis: An Unmet International Need or a Regulatory Risk?-Reference-Cited by-同舟云学术

Biosimilar Drugs for Multiple Sclerosis: An Unmet International Need or a Regulatory Risk?

Published:2019-07-16 Issue:2 Volume:8 Page:177-184
ISSN:2193-8253
Container-title:Neurology and Therapy
language:en
Short-container-title:Neurol Ther

Author:

Rivera Victor M.

Publisher

Springer Science and Business Media LLC

Subject

Neurology (clinical),Neurology

Link

http://link.springer.com/content/pdf/10.1007/s40120-019-0145-0.pdf

Reference26 articles.

1. Hartung DM, Bourdette DN, Ahmed SM, et al. Neurology. 2015;84(21):2185–92.

2. Multiple Sclerosis (MS) drugs-global market projections to 2023: Key players are bayer, Biogen, Merck, Novartis, and Sano fi-Resear chAndMark ets.com (Published Mar 22, 2019). Press Release. https://www.businesswire.com/news/home/20190320052014/en/ . Accessed 23 June 2019.

3. https://www.ocrevus.com . Accessed 23 June 2019.

4. Lublin F, Reingold SC, Cohen JA, et al. Defining the clinical course of multiple sclerosis. The 2013 revisions. Neurology. 2014;83:278–86.

5. http://www.nationalmssociety.org/ Treating-MS/Medicat ions/Mayzant. Accessed 23 June 2019.

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A place for biosimilars in the changing multiple sclerosis treatment landscape;Multiple Sclerosis and Related Disorders;2023-09

2. Use of follow-on fingolimod for multiple sclerosis: Analysis of effectiveness and patient reported outcomes in a real-world clinical setting;Multiple Sclerosis and Related Disorders;2023-09

3. Generic MS medications: Reducing costs without compromising safety;Multiple Sclerosis Journal;2022-11-07

4. Use of follow-on disease-modifying treatments for multiple sclerosis: Consensus recommendations;Multiple Sclerosis Journal;2022-08-24

5. Blood transcriptome profiling captures dysregulated pathways and response to treatment in neuroimmunological disease;EBioMedicine;2019-11